Press Releases

« Back
Printer Friendly Version  View printer-friendly version
Lion Biotechnologies to Host Conference Call to Discuss Third Quarter 2016 Financial and Operating Results on Friday, November 4, 2016

SAN CARLOS, CA -- (Marketwired) -- 10/28/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that it will report its third quarter 2016 financial and operating results before the open of the U.S. financial markets on Friday, November 4, 2016. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:30 a.m. ET.

In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international). The live webcast can be accessed under "Events and Presentation" in the "Investors" section of the Company's website at or you may use the link:

A replay of the call will be available one hour after the end of the call on November 4, 2016 until 8:30 a.m. ET on November 11, 2016. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 3946579. The archived webcast will be available for thirty days in the Investors section of Lion Biotechnologies' website at

About Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte technology (TIL) for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute, MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit

Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.

Media Contact:
Alex Ferrara
inVentivHealth Public Relations

Source: Lion Biotechnologies, Inc.

Released October 28, 2016